Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT02318147 Recruiting - Acute Pancreatitis Clinical Trials

Fecal Microbiota Transplantation for Pancreatitis With Infectious Complications(FMTPIC)

Start date: November 2016
Phase: Phase 1
Study type: Interventional

Infectious complications are responsible for most of deaths in acute pancreatitis.Intestinal barrier dysfunction and increased intestinal permeability was associated with bacterial translocation which is believed to prompted these infections.The purpose of this clinical trail is to observe the potential capability of FMT in reduce the bacterial translocation and alleviate infectious complications by the reconstruction of a gut functional state.

NCT ID: NCT02271243 Recruiting - Clinical trials for Laboratory-confirmed Bloodstream Infection

Using Microbial Genomics to Elucidate the Source of Central-line Associated Bloodstream Infections

Start date: November 2014
Phase:
Study type: Observational

Central line-associated bloodstream infections (CLABSIs) are the most common healthcare-associated infection in children and are associated with morbidity and mortality. This study will attempt to identify the source of bloodstream infections (BSIs) in children with CLABSI because we hypothesize that many of the BSIs that are currently classified as CLABSIs are actually laboratory-confirmed bloodstream infections (LCBI) that may be a result of mucosal barrier injury (MBI), also known as MBI-LCBI. In order to study this, we will isolate bacteria from multiple body sites of children that have BSI in order to compare these bacteria to the strain growing in their blood using whole-genome DNA sequencing. We will also evaluate biomarkers of MBI of the respiratory tract and GI tract.

NCT ID: NCT02260102 Recruiting - Infection Clinical Trials

Temocillin Pharmacokinetics in Paediatrics

TEMOPEDI
Start date: February 17, 2016
Phase: Phase 4
Study type: Interventional

Temocillin (6-methoxy-ticarcillin) is a beta-lactam antibiotic with exceptional resistance to most beta-lactamases. In this context, it is now increasingly used as carbapenem-sparing antibiotic in patients with suspected infection by Enterobactreriaceae suspected to produce extended-spectrum beta-lactamases. Little is known about dosing and elimination of temocillin in children. While available literature of temocillin use in paediatrics refers mainly to its clinical efficacy in the treatment of urinary tract infections, the drug is also used for the treatment of suspicion of cholangitis in cirrhotic paediatric patients, and as antibiotic prophylaxis following an hepatic transplant in children (both off-label indications). There is, therefore, a pressing need to explore the pharmacokinetics and pharmacodynamics of temocillin in the paediatric population, in order to provide clear guidance on an appropriate dosing regimen. The study objectives are: (1) characterisation of the pharmacokinetics (PK) of temocillin in 3 paediatric populations, (2) proposal and development of a dosing schedule that can ensure therapeutic concentrations (40% ƒT > MIC) and optimize treatment chances of success, and (3) characterization of MICs of microbiological strains (when available) to temocillin.

NCT ID: NCT02255318 Recruiting - Cancer Clinical Trials

Primary Prevention of Infections Related to Chambers Implantable Catheter by a Taurolodine Lock in Patients With Cancer Receiving Parenteral Nutrition

Start date: January 2015
Phase: N/A
Study type: Interventional

The therapeutic management of patients with cancer often requires the establishment of a chamber implantable catheter. Infections are the main complication of these catheters. These infections may be responsible for a significant impairment of quality of life for patients, and may increase the frequency and duration of hospitalizations. The rate of mortality from these infections is about 17%. The objective of this study is to evaluate the efficacy of a 1.35% taurolidine lock / 4% citrate (TauroLock®) in the primary prevention of infections related to chambers implantable catheter (IRCIC) in cancer patients receiving parenteral nutrition. This is a, randomized, double-blind clinical trial comparing the incidence of IRCIC in patients receiving Taurolidine lock or concession the usual procedure of rinsing with saline (placebo) (pulsed rinsing with 20 mL of serum physiological and clamping catheter positive pressure). The lock will be instilled after the end of the session IV treatment (chemotherapy, parenteral nutrition, transfusion) before closing the catheter. The primary endpoint will be the rate IRCIC in both groups.

NCT ID: NCT02252900 Recruiting - Clinical trials for Infectious Endocarditis

Long-term Clinico-radiological Evolution of Patients With Brain Lesions During Infectious Endocarditis

POST-IMAGE
Start date: December 2013
Phase: N/A
Study type: Interventional

Primary objective: To describe the evolution of cerebral lesions in IE patients (number of patients with abnormal cerebral MRI in acute phase of IE and during follow-up).

NCT ID: NCT02246270 Recruiting - Clinical trials for Recurrent Urinary Tract Infections

Recurrent Urinary Tract Infections and Heparin (RUTIH Trial)

Start date: November 28, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Urinary Tract Infections (UTIs) are the second most common infection in the body. UTIs account for five percent of all visits to primary care physicians. Many women who have had a UTI will develop recurring urinary tract infections. Recent studies suggest that some women who suffer from recurrent UTIs have urinary tracts that allow bacteria to adhere to it more readily than others. Women who suffered from bladder inflammation and recurrent UTIs were noted to have reduced UTIs and bladder inflammation with heparin bladder instillations. Heparin is a highly-sulfated glycosaminoglycan and stored within the secretory granules of mast cells and released only into the vasculature at sites of tissue injury. It has been proposed that, in addition to anticoagulation, the main purpose of heparin is defense at such sites against invading bacteria and other foreign materials. The central question the research is intended to answer is does Heparin bladder instillations decrease UTI rates in patients.

NCT ID: NCT02237859 Recruiting - Clinical trials for Clostridium Difficile Infection

Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection

Start date: August 2014
Phase: Phase 4
Study type: Interventional

We are doing this research study to determine if taking vancomycin in addition to a broad-spectrum antibiotic will decrease the chance of developing recurrent Clostridium difficile infection.

NCT ID: NCT02217046 Recruiting - Infection Clinical Trials

Decrease Implantation Site INFECTION : a Randomized Controlled Trial

Start date: December 2013
Phase: N/A
Study type: Interventional

Cardiovascular implantable electronic device (CIED) infections have been increasing out of proportion to the number of devices implanted the investigators investigated recent trends and possible causes of the increasing numbers of Cardiovascular implantable electronic device infections.

NCT ID: NCT02196753 Recruiting - Complications Clinical Trials

PET CT in Suspected CIED Infection, a Pilot Study - PET Guidance I

PET Guidance I
Start date: March 2014
Phase: N/A
Study type: Observational

The aim of this single-center randomized controlled trial is to assess clinical usefulness of positron emission tomography combined with computed tomography (PET CT) in the diagnostic process of suspected cardiovascular implantable electronic device (CIED) infection (lead dependent infective endocarditis, generator pocket infection, fever of unknown origin).

NCT ID: NCT02167802 Recruiting - Severe Infection Clinical Trials

Construction and Validation of a Tool for Automatic Identification of Care Pathways at Risk of Sub-optimality in the Management of Severe Infections in Children (DIABACT IV)

DIABACT IV
Start date: March 20, 2015
Phase:
Study type: Observational

Community bacterial infection remains to this day a common cause of morbidity and mortality in children, which preventability is a challenge for clinicians. In a previous work, the investigators found that 76% supported children admitted to the ICU for severe bacterial infection were appraised as suboptimal and significantly associated with an increased risk of death. In this context, the investigators seek to identify indicators of extractable data PMSI and SNIIR -AM associated with a higher risk of suboptimal early taking care of children with severe bacterial infection in order to combine them and use them as a score or decision tree that the investigators will validate data from a national prospective multicenter study including 512 children admitted to the ICU for severe infection. The investigators then propose a score associated with a risk of suboptimality care to evaluate the performance of the healthcare system .